BTC/USD continues to decline as weak ETF inflows and futures data pressure prices, with technicals suggesting a drop toward the key $98,000 support level.
Excellent profit margins, understated future earnings potential, and winning the bidding war for Metsera have injected bullishness. Should you buy Pfizer following the Metsera deal?